By replacing short-acting ANP and BNP polypeptides, an anti-NPR1 antibody sustains NPR1 activation for longer heart failure treatment.
C3-carbon linked glutarimide Degronimers recruit cereblon and target proteins to drive selective in vivo degradation with therapeutic potential.
Specific FSHR-binding antibodies improve cancer and infertility treatment while using modular antibody regions to manage production complexity.